Advancement in Beneficial Effects of AVE 0991 : A Brief Review
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
AVE 0991, a non-peptide analogue of Angiotensin-(1-7) [Ang-(1-7)], is orally active and physiologically well tolerated. Several studies have demonstrated that AVE 0991 improves glucose and lipid metabolism, and contains anti-inflammatory, anti-apoptotic, anti-fibrosis, and anti-oxidant effects. Numerous preclinical studies have also reported that AVE 0991 appears to have beneficial effects on a variety of systemic diseases, including cardiovascular, liver, kidney, cancer, diabetes, and nervous system diseases. This study searched multiple literature databases, including PubMed, Web of Science, EMBASE, Google Scholar, Cochrane Library, and the ClinicalTrials.gov website from the establishment to October 2022, using AVE 0991 as a keyword. This literature search revealed that AVE 0991 could play different roles via various signaling pathways. However, the potential mechanisms of these effects need further elucidation. This review summarizes the benefits of AVE 0991 in several medical problems, including the COVID-19 pandemic. The paper also describes the underlying mechanisms of AVE 0991, giving in-depth insights and perspectives on the pharmaceutical value of AVE 0991 in drug discovery and development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Mini reviews in medicinal chemistry - 24(2024), 2 vom: 15., Seite 139-158 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deng, Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AVE 0991 |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 15.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389557523666230328134932 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355030357 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355030357 | ||
| 003 | DE-627 | ||
| 005 | 20240115231823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389557523666230328134932 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM355030357 | ||
| 035 | |a (NLM)36998128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deng, Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advancement in Beneficial Effects of AVE 0991 |b A Brief Review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a AVE 0991, a non-peptide analogue of Angiotensin-(1-7) [Ang-(1-7)], is orally active and physiologically well tolerated. Several studies have demonstrated that AVE 0991 improves glucose and lipid metabolism, and contains anti-inflammatory, anti-apoptotic, anti-fibrosis, and anti-oxidant effects. Numerous preclinical studies have also reported that AVE 0991 appears to have beneficial effects on a variety of systemic diseases, including cardiovascular, liver, kidney, cancer, diabetes, and nervous system diseases. This study searched multiple literature databases, including PubMed, Web of Science, EMBASE, Google Scholar, Cochrane Library, and the ClinicalTrials.gov website from the establishment to October 2022, using AVE 0991 as a keyword. This literature search revealed that AVE 0991 could play different roles via various signaling pathways. However, the potential mechanisms of these effects need further elucidation. This review summarizes the benefits of AVE 0991 in several medical problems, including the COVID-19 pandemic. The paper also describes the underlying mechanisms of AVE 0991, giving in-depth insights and perspectives on the pharmaceutical value of AVE 0991 in drug discovery and development | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AVE 0991 | |
| 650 | 4 | |a anti-apoptotic | |
| 650 | 4 | |a anti-fibrosis. | |
| 650 | 4 | |a anti-inflammatory | |
| 650 | 4 | |a anti-oxidant | |
| 650 | 4 | |a benefits | |
| 650 | 7 | |a AVE 0991 |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 700 | 1 | |a Ding, Wangli |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yingdong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mini reviews in medicinal chemistry |d 2001 |g 24(2024), 2 vom: 15., Seite 139-158 |w (DE-627)NLM121595404 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:2 |g day:15 |g pages:139-158 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389557523666230328134932 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 2 |b 15 |h 139-158 | ||